U.S. Market Intelligence | 10-Year Forecast Included
A U.S.-first WGS assessment can identify where comprehensive genomic profiling may create the strongest value in hematological malignancies
The immediate decision is to identify the clinical use case, commercial pathway and differentiation model that justify further development.
Decision summary
Clinical opportunity
WGS may add value where laboratories need broader genomic characterisation across mutations, copy-number changes and structural variants.
Commercial constraint
Adoption remains dependent on clinical utility, workflow integration, turnaround time, reimbursement and interpretation capability.
Recommended priority
Begin with selected U.S. hematological applications before expanding the offering or geographic scope.
Recommended action
Prioritise the U.S. indication and workflow where WGS can provide measurable value beyond existing testing methods.